1 |
Nguyen Tran MT, Kc R, Hewitt AW. A Taxonomic and Phylogenetic Classification of Diverse Base Editors. CRISPR J 2022. [PMID: 35244489 DOI: 10.1089/crispr.2021.0095] [Reference Citation Analysis]
|
2 |
Piotter E, Mcclements ME, Maclaren RE. The Scope of Pathogenic ABCA4 Mutations Targetable by CRISPR DNA Base Editing Systems—A Systematic Review. Front Genet 2022;12:814131. [DOI: 10.3389/fgene.2021.814131] [Reference Citation Analysis]
|
3 |
Piotter E, McClements ME, MacLaren RE. Therapy Approaches for Stargardt Disease. Biomolecules 2021;11:1179. [PMID: 34439845 DOI: 10.3390/biom11081179] [Reference Citation Analysis]
|
4 |
Bellingrath JS, McClements ME, Kaukonen M, Fischer MD, MacLaren RE. In Silico Analysis of Pathogenic CRB1 Single Nucleotide Variants and Their Amenability to Base Editing as a Potential Lead for Therapeutic Intervention. Genes (Basel) 2021;12:1908. [PMID: 34946856 DOI: 10.3390/genes12121908] [Reference Citation Analysis]
|
5 |
Bansal M, Acharya S, Sharma S, Phutela R, Rauthan R, Maiti S, Chakraborty D. CRISPR Cas9 based genome editing in inherited retinal dystrophies. Ophthalmic Genet 2021;42:365-74. [PMID: 33821751 DOI: 10.1080/13816810.2021.1904421] [Reference Citation Analysis]
|
6 |
Liu W, Li L, Jiang J, Wu M, Lin P. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precis Clin Med 2021;4:179-91. [PMID: 34541453 DOI: 10.1093/pcmedi/pbab014] [Reference Citation Analysis]
|
7 |
da Costa BL, Levi SR, Eulau E, Tsai YT, Quinn PMJ. Prime Editing for Inherited Retinal Diseases. Front Genome Ed 2021;3:775330. [PMID: 34901928 DOI: 10.3389/fgeed.2021.775330] [Reference Citation Analysis]
|
8 |
Schneider N, Sundaresan Y, Gopalakrishnan P, Beryozkin A, Hanany M, Levanon EY, Banin E, Ben-Aroya S, Sharon D. Inherited retinal diseases: Linking genes, disease-causing variants, and relevant therapeutic modalities. Prog Retin Eye Res 2021;:101029. [PMID: 34839010 DOI: 10.1016/j.preteyeres.2021.101029] [Reference Citation Analysis]
|